Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy:  5-Year Safety From VOYAGE (VOY)1&2

Andrew  Blauvelt; Diamant Thaci; Kim Papp; Vincent  Ho; Kamran Ghoreschi; Byung Soo Kim; Megan  Miller; Yaung-Kaung  Shen; Yin You; Jenny Yu; Ya-Wen Yang; Jeffrey Crowley; Peter Foley

doi:10.25251/skin.6.supp.2

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Diamant Thaci

University of Lübeck, Lübeck, Germany

Kim Papp

Probity Medical Research, Waterloo, ON, Canada

Vincent Ho

University of British Columbia, Vancouver, BC

Kamran Ghoreschi

Charité – Universitätsmedizin, Berlin, Germany

Byung Soo Kim

Pusan National University

Megan Miller

Janssen Research and Development

Yaung-Kaung Shen

Janssen Research and Development

Yin You

Janssen Research and Development

Jenny Yu

Janssen Research and Development

Ya-Wen Yang

Janssen Pharma

Jeffrey Crowley

Bakersfield Dermatology and Skin Cancer Medical Group

Peter Foley

The University of Melbourne

Keywords

psoriasis

Abstract

N/A

References

1. Wong PKK, et al. Curr Rheumatol Rep. 2018;20:64.

2. Plachouri K-M, Georgiou S. Int J Dermatol. 2019;58:1008-13.

3. Reich K, et al. Br J Dermatol. 2021 Jun 9. doi: 10.1111/bjd.20568. Online ahead of print.

4. Reich K, et al. J Am Acad Dermatol. 2020;82:936-45.

Poster PDF

Published

Mar 4, 2022

DOI https://doi.org/10.25251/skin.6.supp.2

How to Cite

Blauvelt, A. ., Thaci, D., Papp, K., Ho, V. ., Ghoreschi, K., Kim, B. S., Miller, M. ., Shen, Y.-K. ., You, Y., Yu, J., Yang, Y.-W., Crowley, J., & Foley, P. (2022). Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 . SKIN The Journal of Cutaneous Medicine, 6(2), s2. https://doi.org/10.25251/skin.6.supp.2

Issue

Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

Section

Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley, Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Mark Lebwohl, Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, David Adam, H. Chih-ho Hong, Leon Kircik, Matthew Zirwas, Patrick Burnett, Robert Higham, David Krupa, David Berk, Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Andrew Blauvelt, Anderas Wollenberg, Andrew Pink, Ketty Peris, April Armstrong , Lynda Spelman, Hidehisa Saeki, Charles Lynde, Pedro Herranz, Sebastien Barbarot, Eric Simpson, Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, George Han, Steve Tyring, Jennifer Soung, Tae Oh, Leah Davis, Veerle Vanoorden, Mark Lebwohl, Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, Andrew Blauvelt, 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu, Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Joe Merola, Howard Sofen, Diamant Thaci, Carle Paul, Shinichi Imafuku, Subhashis Banerjee, April Armstrong , Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Neil Korman, Thierry Passeron, Kenneth Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Diamant Thaçi, Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Andrew Blauvelt, Joseph F Fowler, Jr., Ellen Schuck, Julia Jauch, Heike Woehling, Craig L Leonardi, A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Bruce Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Jonathan Barker, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle Paul, Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)